Intuniv 3 mg prolonged-release tablets clinical trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder

This study is looking at a medicine called Intuniv for children and teenagers aged 6 to 17 with ADHD. We want to see how safe and effective it is compared to another medicine and a dummy pill, and find the best dose.